|
ROCURONIUM BROMIDE |
| 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(Acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan- 16-yl)-1-(2- propenyl)pyrrolidinium; Zemuron; 1-Allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino- 5alpha- androstan- 16beta-yl)pyrrolidinium 17-acetate bromide; |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
119302-91-9 (Bromide), 143558-00-3 (Parent) |
|
EINECS RN |
|
|
FORMULA |
C32H53BrN2O4 |
|
MOLE WEIGHT |
609.68 |
|
SOURCE |
|
|
CLASSIFICATION |
Neuromuscular blocking agent / Aminosteroid |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
pale yellow crystalline power |
|
MELTING POINT |
|
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
100 mg/ml |
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents. |
| DECOMPOSITION PRODUCTS |
Carbon oxides, nitrogen oxides, Hydrogen bromide gas |
| POLYMERIZATION | Has not been reported |
|
NFPA RATINGS |
Health: 0 Flammability: 0 Reactivity: 0 |
|
|
|
POTENTIAL HEALTH EFFECTS |
|
|
HAZARD NOTES |
Target Organs: Nerves, Skeletal muscle. |
|
EYE |
May cause eye irritation. |
|
SKIN |
May be harmful if absorbed through skin. May cause skin irritation. |
|
INGESTION |
May be harmful if swallowed. |
|
INHALATION |
May be harmful if inhaled. May cause respiratory tract irritation. |
| TARGET ORGANS |
Immune system |
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
|
| HAZARD CLASS |
|
| PACKING GROUP |
|
| HAZARD SYMBOL |
|
|
RISK PHRASES |
|
|
SAFETY PHRASES |
22-24/25 |
|
|
| EXTERNAL LINKS & GENERAL INFORMATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Neuromuscular blockers relax skeletal muscle tone by blocking transmission of key neurotransmitters through the neuron receptors at the neuromuscular junction (NMJ). They are divided into two major categories, depolarizing and non-depolarizing neuromuscular blockers, corresponding to the manner in which they exert their therapeutic effect. Depolarizing neuromuscular blocking agents mimic the effects of the neurotransmitter acetylcholine (ACh) and change the interaction between ACh and neuron receptors. Blockade occurs because membranes surrounding the neuromuscular junction become unresponsive to typical ACh-receptor interaction. Non-depolarizing neuromuscular blockers bind to receptors to prevent transmission of impulses through ACh neurotransmitters. Neuromuscular blockers are primarily used in a clinical or hospital setting. In the United States, they are known by several generic and brand names, including atracurium (Tracurium), cisatracurium (Nimbex), doxacurium (Neuromax), mivacurium (Mivacron), pancuronium (Pavulon), pipecuronium (Arduan), rocuronium (Zemeron), succinylcholine (Anectine), tubocurarine, and vecuronium (Norcuron). (http://www.healthline.com/) Rocuronium is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and an intermediate duration of action. The drug acts by binding competitively to cholinergic receptors at the motor end-plate to antagonize the action of acetylcholine, an effect which is reversible in the presence of acetylcholinesterase inhibitors, such as neostigmine and edrophonium. (http://www.rxmed.com/)Rocuronium is a neuromuscular blocking agent, used as the bromide salt as an adjunct in general anesthesia to facilitate endotracheal intubation and as a skeletal muscle relaxant during surgery or mechanical ventilation Pharmacological Actions:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
white to yellow powder |
|
IDENTIFICATION |
pass Test A,B,C |
|
ASSAY |
99.0 - 101.0% |
|
WATER |
4.0% max |
|
OPTICAL ROTATION |
+28° ~ +30° |
|
RELATED SUBSTANCES |
1.5% max |
|
LOSS ON DRYING |
0.5% max |
|
HEAVY METALS |
10ppm max |
|
|
| PRICE INFORMATION |